Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.15
DEPO's Cash to Debt is ranked lower than
90% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. DEPO: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 11.79 Max: No Debt
Current: 0.15
Equity to Asset 0.23
DEPO's Equity to Asset is ranked lower than
93% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DEPO: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s Equity to Asset Range Over the Past 10 Years
Min: -1.33  Med: 0.36 Max: 0.89
Current: 0.23
-1.33
0.89
F-Score: 3
Z-Score: 0.79
M-Score: 0.27
WACC vs ROIC
10.70%
-3.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -14.71
DEPO's Operating margin (%) is ranked lower than
81% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. DEPO: -14.71 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s Operating margin (%) Range Over the Past 10 Years
Min: -435.63  Med: -5.11 Max: 72.49
Current: -14.71
-435.63
72.49
Net-margin (%) -22.10
DEPO's Net-margin (%) is ranked lower than
83% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. DEPO: -22.10 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s Net-margin (%) Range Over the Past 10 Years
Min: -415.23  Med: -8.64 Max: 75.05
Current: -22.1
-415.23
75.05
ROE (%) -21.92
DEPO's ROE (%) is ranked lower than
80% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. DEPO: -21.92 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s ROE (%) Range Over the Past 10 Years
Min: -90.05  Med: 20.07 Max: 532.43
Current: -21.92
-90.05
532.43
ROA (%) -6.93
DEPO's ROA (%) is ranked lower than
76% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. DEPO: -6.93 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s ROA (%) Range Over the Past 10 Years
Min: -66.64  Med: -1.47 Max: 73.87
Current: -6.93
-66.64
73.87
ROC (Joel Greenblatt) (%) -25.03
DEPO's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. DEPO: -25.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2282.52  Med: 49.51 Max: 8060.52
Current: -25.03
-2282.52
8060.52
Revenue Growth (3Y)(%) 51.90
DEPO's Revenue Growth (3Y)(%) is ranked higher than
95% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. DEPO: 51.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.4  Med: 35.40 Max: 517.8
Current: 51.9
-74.4
517.8
EPS Growth (3Y)(%) 33.20
DEPO's EPS Growth (3Y)(%) is ranked higher than
82% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. DEPO: 33.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.8  Med: -5.10 Max: 180.8
Current: 33.2
-58.8
180.8
» DEPO's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DEPO Guru Trades in Q1 2015

Joel Greenblatt 1,414,563 sh (+16.11%)
Paul Tudor Jones 42,414 sh (+0.12%)
Steven Cohen Sold Out
» More
Q2 2015

DEPO Guru Trades in Q2 2015

Paul Tudor Jones 26,100 sh (-38.46%)
Joel Greenblatt 842,188 sh (-40.46%)
» More
Q3 2015

DEPO Guru Trades in Q3 2015

Jim Simons 104,146 sh (New)
Paul Tudor Jones 40,800 sh (+56.32%)
Joel Greenblatt 264,236 sh (-68.63%)
» More
Q4 2015

DEPO Guru Trades in Q4 2015

John Hussman 200,000 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones 30,900 sh (-24.26%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.35
DEPO's Forward P/E is ranked higher than
74% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. DEPO: 10.35 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 9.44
DEPO's Price/Owner Earnings (ttm) is ranked higher than
89% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. DEPO: 9.44 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DEPO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.68  Med: 7.41 Max: 196
Current: 9.44
2.68
196
P/B 3.24
DEPO's P/B is ranked lower than
58% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. DEPO: 3.24 )
Ranked among companies with meaningful P/B only.
DEPO' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.33 Max: 48.18
Current: 3.24
2
48.18
P/S 2.96
DEPO's P/S is ranked lower than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. DEPO: 2.96 )
Ranked among companies with meaningful P/S only.
DEPO' s P/S Range Over the Past 10 Years
Min: 1.38  Med: 3.52 Max: 378.57
Current: 2.96
1.38
378.57
PFCF 7.11
DEPO's PFCF is ranked higher than
88% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. DEPO: 7.11 )
Ranked among companies with meaningful PFCF only.
DEPO' s PFCF Range Over the Past 10 Years
Min: 2.31  Med: 9.15 Max: 265.87
Current: 7.11
2.31
265.87
POCF 7.04
DEPO's POCF is ranked higher than
84% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. DEPO: 7.04 )
Ranked among companies with meaningful POCF only.
DEPO' s POCF Range Over the Past 10 Years
Min: 2.28  Med: 8.96 Max: 251.36
Current: 7.04
2.28
251.36
EV-to-EBITDA 60.84
DEPO's EV-to-EBITDA is ranked lower than
89% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. DEPO: 60.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: -2.10 Max: 124.5
Current: 60.84
-582.9
124.5
Shiller P/E 128.96
DEPO's Shiller P/E is ranked lower than
85% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. DEPO: 128.96 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s Shiller P/E Range Over the Past 10 Years
Min: 84.17  Med: 128.76 Max: 387.25
Current: 128.96
84.17
387.25
Current Ratio 1.41
DEPO's Current Ratio is ranked lower than
77% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 1.41 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.68 Max: 12.5
Current: 1.41
0.29
12.5
Quick Ratio 1.36
DEPO's Quick Ratio is ranked lower than
64% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. DEPO: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.54 Max: 12.5
Current: 1.36
0.29
12.5
Days Inventory 50.68
DEPO's Days Inventory is ranked higher than
84% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. DEPO: 50.68 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 50.93  Med: 226.72 Max: 613.73
Current: 50.68
50.93
613.73
Days Sales Outstanding 75.75
DEPO's Days Sales Outstanding is ranked lower than
51% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. DEPO: 75.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 347.08
Current: 75.75
12.13
347.08
Days Payable 68.84
DEPO's Days Payable is ranked lower than
53% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. DEPO: 68.84 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 128.77 Max: 1113.92
Current: 68.84
30.8
1113.92

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.98
DEPO's Price/Projected FCF is ranked higher than
59% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. DEPO: 1.98 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.48  Med: 3.37 Max: 335
Current: 1.98
1.48
335
Price/Median PS Value 0.86
DEPO's Price/Median PS Value is ranked higher than
76% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. DEPO: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.61  Med: 4.26 Max: 270
Current: 0.86
0.61
270
Price/Graham Number 0.96
DEPO's Price/Graham Number is ranked higher than
79% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. DEPO: 0.96 )
Ranked among companies with meaningful Price/Graham Number only.
DEPO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.7  Med: 0.98 Max: 7.48
Current: 0.96
0.7
7.48
Earnings Yield (Greenblatt) (%) -2.26
DEPO's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. DEPO: -2.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.24  Med: 17.25 Max: 266.4
Current: -2.26
-2.24
266.4

More Statistics

Revenue(Mil) $343
EPS $ -1.27
Beta1.69
Short Percentage of Float29.73%
52-Week Range $12.25 - 33.74
Shares Outstanding(Mil)60.90

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 495 603 700
EPS($) 1.26 1.67 2.24
EPS without NRI($) 1.26 1.67 2.24

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TSE:8129, SZSE:002737, SZSE:000650, NAS:RDUS, NAS:IRWD, TSE:4569 » details
Traded in other countries:DPO.Germany,
DepoMed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed to Present at Healthcare Conferences in May May 03 2016
Depomed to Present at Healthcare Conferences in May May 03 2016
Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016 Apr 28 2016
Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016 Apr 28 2016
Sohn Preview: Starboard Value Adds Infoblox to Already Full Plate Apr 27 2016
[$$] Depomed Says Starboard Has Month to Call Shareholder Meeting Apr 25 2016
Depomed gives Starboard chance for meeting to replace board Apr 25 2016
Depomed gives Starboard chance for meeting to replace board Apr 25 2016
Depomed says Starboard has a month to request for shareholder meeting Apr 25 2016
Depomed Announces Record Date to Determine Shareholders Entitled to Request Special Meeting Apr 25 2016
DEPOMED INC Files SEC form 8-K, Other Events Apr 25 2016
Depomed Announces Record Date to Determine Shareholders Entitled to Request Special Meeting Apr 25 2016
Why This Hedge Fund Activist Wants to Replace Yahoo’s Entire Board Apr 19 2016
Activist shareholder: Board change 'required' at East Bay drug company Apr 18 2016
Depomed Inc (DEPO): Starboard Value Snatches Up Another 1.5 Million Shares Apr 16 2016
Activist Investor Reaffirms Stance On Depomed, Says 'Meaningful Change Is Needed' Apr 15 2016
East Bay drug company avoids 'distracting' shareholder fight by withdrawing reincorporation plan Apr 15 2016
[$$] Starboard to Continue Proxy Fight Against Depomed Apr 15 2016
Starboard presses on with push to replace Depomed's board Apr 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK